CG
Pre-Approval PRO BETAAlso known as: CG Oncology, Inc., CG Pharmaceuticals, Inc
Slowing Activity
No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 9/16/2024
Pipeline by Phase
Therapeutic Focus
Clinical Trials (8)
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
Started: 10/27/2020
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
Started: 12/14/2023
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Started: 9/16/2024
Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer
Started: 3/1/2014
Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin
Started: 12/8/2020
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
Started: 3/1/2014
Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure
Started: 6/2/2015
A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma
Started: 8/15/2022